ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments

ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments

In the recent years, it was recognized that type-2 inflammation links many forms of nasal polyposis with severe asthma. Thus, some biological drugs developed for severe asthma appeared to exert an effect on nasal polyposis. So far, there are several trials supporting this concept; therefore, some mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carlo Lombardi, MD, Riccardo Asero, MD, Diego Bagnasco, MD, Francesco Blasi, MD, Matteo Bonini, MD, Mario Bussi, MD, Rikki F. Canevari, MD, Giorgio Walter Canonica, MD, Paolo Castelnuovo, MD, Lorenzo Cecchi, MD, Lorenzo Cosmi, MD, Matteo Gelardi, MD, Enrico Heffler, MD, Luciana Indinnimeo, MD, Massimo Landi, MD, Amelia Licari, MD, Francesco Liotta, MD, Alberto Macchi, MD, Luca Malvezzi, MD, Gianluigi Marseglia, MD, Claudio Micheletto, MD, Antonino Musarra, MD, Diego Peroni, MD, Giorgio Piacentini, MD, Venerino Poletti, MD, Luca Richeldi, MD, Angela Santoni, MD, Michele Schiappoli, MD, Gianenrico Senna, MD, Adriano Vaghi, MD, Alberto Villani, MD, Giovanni Passalacqua, MD
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Nasal polyps
CRSwNP
Biological antibodies
ARIA
Personalized medicine
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/4ccea6e57c304ff7bb0926fa46f35dac
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:In the recent years, it was recognized that type-2 inflammation links many forms of nasal polyposis with severe asthma. Thus, some biological drugs developed for severe asthma appeared to exert an effect on nasal polyposis. So far, there are several trials supporting this concept; therefore, some monoclonal antibodies for severe asthma were assessed also in polyposis, with promising results. Since different specialists are involved in the management of nasal polyposis (eg, pulmonologists, ENT, allergists), it was felt that an educational and informative document was needed to better identify the indications of biologicals in nasal polyposis. We collected the main Italian Scientific Societies, and prepared (under the Allergic Rhinitis and its Impact on Asthma, ARIA) a document endorsed by all Societies, to provide a provisional statement for the future use of monoclonal antibodies as a medical treatment for polyposis. It is the first nationwide endorsed document on this aspect. The current pathogenic knowledge and the experimental evidence are herein reviewed, and some suggestions for a correct prescription and follow-up are provided.

Ejemplares similares